Pharmacy & Drug Policy
Expert articles and analysis related to pharmacy & drug policy.
AI Summary — Last 7 Days
Synthesis:
Pharmacy policy for value-based care stakeholders is being shaped by the finalization of the CY 2027 Medicare Advantage and Part D rule, which sets new directions for medication adherence metrics and plan sponsor accountability. CMS’s continued reliance on the proportion of days covered (PDC) as a preferred adherence measure is under scrutiny, as concerns mount about its accuracy and implications for quality ratings tied to payment, raising the stakes for providers and ACOs seeking alignment between medication management and value-based contracts. At the same time, emerging tensions around high-cost therapies and benefit design—such as cost-sharing for cell and gene therapies—underscore ongoing challenges in balancing access, affordability, and quality within population health strategies. See: [Crowell & Moring LLP on CY 2027 Medicare Advantage and Part D Rule](https://news.google.com/rss/articles/CBMi2AFBVV95cUxOQ2NaZF9rVlRwVllnUWlfamQtX05BeDZpYkdJdEJraTJ1alNWRFNsRE9Ca0E1ZlUtZlp1ZDlPLXBxUkMxT3NMb2FLeFg3bklfNjdiMjNOYlR1Qm5yVFVTSmFLSUsyLW9GOHB3RDJPRG54ay1QUjhJcTZXOWlBaW1Mck9jTlk1Tk55OEds
Related Articles
STAT+: The PBMs fight back, and arbitration doesn’t lose
We unpack the contentious fight over drug price transparency.
STAT+: PBMs warn Trump’s proposal to disclose drug prices is illegal
Pharma industry middlemen are pushing back on a major drug price transparency proposal.
Stakeholders urge Labor Department to finalize PBM transparency rule
Employers, lawmakers and more said regulators should hustle to get disclosure mandates for the controversial drug middlemen across the finish line, while PBMs slammed the rule as illegal, unnecessary ...
Rising Drug Prices Mean Consumers Bear the Cost
Rising Drug Prices Mean Consumers Bear the Cost AHIP
New Bill Seeks to Lower Out-of-Pocket Drug Costs
New Bill Seeks to Lower Out-of-Pocket Drug Costs MedCity News
Will CMS' new BALANCE model make GLP-1s more affordable?
Will CMS' new BALANCE model make GLP-1s more affordable? Advisory Board
Two visions for value – Why GCEA and HEMA clash on drug pricing
That is the title of my latest Perspectives from the Healthcare Economist article published in The Evidence Base this week. Here is the teaser: In this guest column, healthcare economist Jason Shafrin...
AHA urges HRSA to abandon 340B rebate model that will cost billions and jeopardize access to care for millions
AHA urges HRSA to abandon 340B rebate model that will cost billions and jeopardize access to care for millions American Hospital Association
AHA urges HRSA to axe 340B model that would cost hospitals $1B+ a year
AHA urges HRSA to axe 340B model that would cost hospitals $1B+ a year Becker's Hospital Review
Federal 340B overhaul bill unlikely this year
A bipartisan Senate effort at 340B program reform is likely dead this Congress, according to lobbyists and policy watchers. The so-called gang of six group of senators has been working on an overhaul ...